GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OWC Pharmaceutical Research Corp (OTCPK:OWCP) » Definitions » Piotroski F-Score

OWC Pharmaceutical Research (OWC Pharmaceutical Research) Piotroski F-Score : 0 (As of Jun. 05, 2024)


View and export this data going back to 2008. Start your Free Trial

What is OWC Pharmaceutical Research Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

OWC Pharmaceutical Research has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for OWC Pharmaceutical Research's Piotroski F-Score or its related term are showing as below:


OWC Pharmaceutical Research Piotroski F-Score Historical Data

The historical data trend for OWC Pharmaceutical Research's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OWC Pharmaceutical Research Piotroski F-Score Chart

OWC Pharmaceutical Research Annual Data
Trend Dec08 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only 3.00 3.00 1.00 3.00 3.00

OWC Pharmaceutical Research Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 3.00 2.00 2.00 2.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep19) TTM:Last Year (Sep18) TTM:
Net Income was -5.08 + -1 + 7.707 + -0.287 = $1.34 Mil.
Cash Flow from Operations was -0.751 + -0.665 + -0.955 + -0.372 = $-2.74 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Sep18)
to the end of this year (Sep19) was
(4.312 + 3.553 + 2.949 + 2.335 + 1.773) / 5 = $2.9844 Mil.
Total Assets at the begining of this year (Sep18) was $4.31 Mil.
Long-Term Debt & Capital Lease Obligation was $0.02 Mil.
Total Current Assets was $1.70 Mil.
Total Current Liabilities was $0.54 Mil.
Net Income was -1.477 + -0.977 + -3.209 + -0.992 = $-6.66 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Sep17)
to the end of last year (Sep18) was
(1.218 + 1.061 + 0.736 + 4.774 + 4.312) / 5 = $2.4202 Mil.
Total Assets at the begining of last year (Sep17) was $1.22 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $4.28 Mil.
Total Current Liabilities was $0.40 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

OWC Pharmaceutical Research's current Net Income (TTM) was 1.34. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

OWC Pharmaceutical Research's current Cash Flow from Operations (TTM) was -2.74. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep18)
=1.34/4.312
=0.31076067

ROA (Last Year)=Net Income/Total Assets (Sep17)
=-6.655/1.218
=-5.46387521

OWC Pharmaceutical Research's return on assets of this year was 0.31076067. OWC Pharmaceutical Research's return on assets of last year was -5.46387521. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

OWC Pharmaceutical Research's current Net Income (TTM) was 1.34. OWC Pharmaceutical Research's current Cash Flow from Operations (TTM) was -2.74. ==> -2.74 <= 1.34 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep19)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep18 to Sep19
=0.021/2.9844
=0.00703659

Gearing (Last Year: Sep18)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep17 to Sep18
=0/2.4202
=0

OWC Pharmaceutical Research's gearing of this year was 0.00703659. OWC Pharmaceutical Research's gearing of last year was 0. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep19)=Total Current Assets/Total Current Liabilities
=1.695/0.543
=3.12154696

Current Ratio (Last Year: Sep18)=Total Current Assets/Total Current Liabilities
=4.279/0.401
=10.67082294

OWC Pharmaceutical Research's current ratio of this year was 3.12154696. OWC Pharmaceutical Research's current ratio of last year was 10.67082294. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

OWC Pharmaceutical Research's number of shares in issue this year was 232.581. OWC Pharmaceutical Research's number of shares in issue last year was 148.975. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

OWC Pharmaceutical Research's gross margin of this year was . OWC Pharmaceutical Research's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep18)
=0/4.312
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep17)
=0/1.218
=0

OWC Pharmaceutical Research's asset turnover of this year was 0. OWC Pharmaceutical Research's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+1+0+0+0+0+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

OWC Pharmaceutical Research has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

OWC Pharmaceutical Research  (OTCPK:OWCP) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


OWC Pharmaceutical Research Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of OWC Pharmaceutical Research's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


OWC Pharmaceutical Research (OWC Pharmaceutical Research) Business Description

Traded in Other Exchanges
N/A
Address
2 Ben Gurion Street, Ramat Gan, ISR, 5257334
OWC Pharmaceutical Research Corp is a medical cannabis research and development company. The firm through its subsidiary researches and develops cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder (PTSD), migraine, sexual function and skin disorders. It also provides consulting services to governmental and private entities to assist them with developing and implementing tailor-made medical cannabis program.
Executives
Asher Zwebner director, officer: CHIEF FINANCIAL OFFICER CDOOR CORPORATION, 20 A REHOV SHAREI TORAH BAYIT VEGAN, JERUSALEM L3 96387

OWC Pharmaceutical Research (OWC Pharmaceutical Research) Headlines